Understanding the complications of antiretroviral drugs
- PMID: 18611156
- PMCID: PMC3170412
- DOI: 10.1086/590155
Understanding the complications of antiretroviral drugs
Comment on
-
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.Clin Infect Dis. 2008 Aug 15;47(4):567-74. doi: 10.1086/590154. Clin Infect Dis. 2008. PMID: 18636958 Free PMC article. Clinical Trial.
References
-
- Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60. - PubMed
-
- Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–8. - PubMed
-
- Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493–505. - PubMed
-
- Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep. 2005;2:39–50. - PubMed
-
- Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor–, nonnucleoside reverse transcriptase inhibitor–, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor–based strategy. J Acquir Immune Defic Syndr. 2007;44:506–17. - PubMed
